These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Possible use of saliva in the diagnostics and treatment--review of the literature]. Klichowska-Palonka M; Bachanek T Przegl Lek; 2011; 68(2):114-7. PubMed ID: 21751521 [TBL] [Abstract][Full Text] [Related]
6. Salivary diagnostics and its impact in dentistry, research, education, and the professional community. Slavkin HC; Fox CH; Meyer DM Adv Dent Res; 2011 Oct; 23(4):381-6. PubMed ID: 21917749 [TBL] [Abstract][Full Text] [Related]
7. The need for increased oversight of genetic testing: a detailed look at the genetic testing process. Bonnin DC Houst J Health Law Policy; 2003; 4(1):149-80. PubMed ID: 16596751 [No Abstract] [Full Text] [Related]
8. The use of genetic testing in the health insurance industry: the creation of a "biologic underclass". O'Hara S Southwest Univ Law Rev; 1993; 22(4):1211-28. PubMed ID: 11659756 [No Abstract] [Full Text] [Related]
9. Salivary diagnostic testing: a "game changer" for patient evaluation. Wright TA Compend Contin Educ Dent; 2011; 32 Spec No 4():28-9. PubMed ID: 22195346 [No Abstract] [Full Text] [Related]
10. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. Phillips KA; Van Bebber SL Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395 [TBL] [Abstract][Full Text] [Related]
11. Body parts: FDA regulation of human tissue banks. Barons J Food Drug Cosmet Med Device Law Dig; 1996; 13(1):26-35. PubMed ID: 11658087 [No Abstract] [Full Text] [Related]
12. Development of vaccines to meet public health needs: incentives and obstacles. Russell PK Risk; 1996; 7(3):239-52. PubMed ID: 11655077 [No Abstract] [Full Text] [Related]
13. DNA microarrays as salivary diagnostic tools for characterizing the oral cavity's microbial community. Smoot LM; Smoot JC; Smidt H; Noble PA; Könneke M; McMurry ZA; Stahl DA Adv Dent Res; 2005 Jun; 18(1):6-11. PubMed ID: 15998937 [No Abstract] [Full Text] [Related]
15. An insurance view on genetic testing. Jaeger AS Forum Appl Res Public Policy; 1993; 8(3):23-5. PubMed ID: 11652661 [No Abstract] [Full Text] [Related]
16. Salivary markers of systemic disease: noninvasive diagnosis of disease and monitoring of general health. Lawrence HP J Can Dent Assoc; 2002 Mar; 68(3):170-4. PubMed ID: 11911813 [TBL] [Abstract][Full Text] [Related]
17. In search of a coherent framework: options for FDA oversight of genetic tests. Javitt GH Food Drug Law J; 2007; 62(4):617-52. PubMed ID: 18557224 [No Abstract] [Full Text] [Related]
18. The Human Genome Project in the United States: a perspective on the commercial, ethical, legislative and health care issues. Mackler BF; Barach M J Int Bioethique; 1991; 2(3):149-57. PubMed ID: 11654898 [TBL] [Abstract][Full Text] [Related]
19. Direct-to-consumer genetic tests, government oversight, and the First Amendment: what the government can (and can't) do to protect the public's health. Javitt GH; Stanley E; Hudson K Oklahoma Law Rev; 2004; 57(2):251-302. PubMed ID: 15658034 [No Abstract] [Full Text] [Related]
20. Forget Washington: state laws threaten to restrict genetic research, too. Fox JL J NIH Res; 1997 Nov; 9(11):19-20. PubMed ID: 11656800 [No Abstract] [Full Text] [Related] [Next] [New Search]